Tech Company Financing Transactions
Totus Medicines Funding Round
DCVC Bio, Camford Capital and Northpond Ventures participated in a $66 million Series B funding round for Totus Medicines. This VC investment round was announced on 12/15/2023.
Transaction Overview
Company Name
Announced On
12/15/2023
Transaction Type
Venture Equity
Amount
$66,000,000
Round
Series B
Investors
Proceeds Purpose
The Series B financing will be used to advance Totus' clinical program, expand the pipeline, and evolve the platform.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
700 Main St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Founded in 2019, Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome. Totus is based in Cambridge, Massachusetts.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neil Dhawan
Chief Financial Officer
Samuel Singer
Vice President
John MacDougall
VP - Administration
Jenna Stein
VP - Engineering
Ryan Tarver
VP - Human Resources
Daisy Chhokar
VP - Operations
Erika Whyte
Browse more venture capital transactions:
Prev: 12/14/2023: FineCell venture capital transaction
Next: 12/15/2023: Spotta venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs